Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Mar 31, 2026
Filing excerpt
In January 2026, we received United States Food and Drug Administration approval for the SAPIEN 3 transcatheter pulmonic valve delivery system, an advancement designed specifically to support pediatric and adult patients living with congenital heart disease.